361 related articles for article (PubMed ID: 11236033)
41. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
42. Clinical trials of single-agent trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
[TBL] [Abstract][Full Text] [Related]
43. [Use of trastuzumab in the therapy of breast cancer].
Riemer AB; Zielinski CC
Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
[TBL] [Abstract][Full Text] [Related]
44. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
45. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
46. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells.
Kuwada SK; Scaife CL; Kuang J; Li X; Wong RF; Florell SR; Coffey RJ; Gray PD
Int J Cancer; 2004 Mar; 109(2):291-301. PubMed ID: 14750183
[TBL] [Abstract][Full Text] [Related]
47. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
48. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
Järvinen TA; Liu ET
Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
50. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Saxena R; Dwivedi A
Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
[TBL] [Abstract][Full Text] [Related]
51. HER-2 signaling and inhibition in breast cancer.
Browne BC; O'Brien N; Duffy MJ; Crown J; O'Donovan N
Curr Cancer Drug Targets; 2009 May; 9(3):419-38. PubMed ID: 19442060
[TBL] [Abstract][Full Text] [Related]
52. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
53. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Menendez JA; Vellon L; Colomer R; Lupu R
Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
[TBL] [Abstract][Full Text] [Related]
54. LGR5 is a biomarker for stratification of HER-2 positive breast cancer patients and personalized treatment.
Chen C; Zhang C; Xu JM; Han Y
Med Hypotheses; 2013 Sep; 81(3):439-42. PubMed ID: 23830593
[TBL] [Abstract][Full Text] [Related]
55. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
Nahta R; Hung MC; Esteva FJ
Cancer Res; 2004 Apr; 64(7):2343-6. PubMed ID: 15059883
[TBL] [Abstract][Full Text] [Related]
56. The role of HER2 in angiogenesis.
Kumar R; Yarmand-Bagheri R
Semin Oncol; 2001 Oct; 28(5 Suppl 16):27-32. PubMed ID: 11706393
[TBL] [Abstract][Full Text] [Related]
57. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
Abuharbeid S; Apel J; Zugmaier G; Knabbe C; Sander M; Gilbert S; Czubayko F; Aigner A
Naunyn Schmiedebergs Arch Pharmacol; 2005 Feb; 371(2):141-51. PubMed ID: 15700118
[TBL] [Abstract][Full Text] [Related]
59. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
60. HER-2/neu and topoisomerase IIalpha in breast cancer.
Järvinen TA; Liu ET
Breast Cancer Res Treat; 2003 Apr; 78(3):299-311. PubMed ID: 12755489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
